Siramesine

 

Topic mentions per year

Topic mentions per year

2001-2017
012320012017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Glioblastoma is the most frequent and most malignant brain tumor with the patients having a median survival of only 14.6 months… (More)
Is this relevant?
2017
2017
Drug addiction is a chronic, debilitating disease that affects millions of people around the world causing a substantial societal… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
A sigma-2 receptor agonist siramesine has been shown to trigger cell death of cancer cells and to exhibit a potent anticancer… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
PURPOSE The aim of the present study was to examine the effects of the sigma-2 receptor agonist, siramesine, on morphology… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 6
  • figure 7
Is this relevant?
2008
2008
A sigma-2 receptor ligand siramesine induces lysosomal leakage and cathepsin-dependent death of cancer cells in vitro and… (More)
Is this relevant?
2008
2008
Siramesine (SRM) is a sigma-2 receptor agonist which has been recently shown to inhibit growth of cancer cells. Fluorescence… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Acquired resistance to classic caspase-mediated apoptosis is a common problem for the treatment of human cancer. Here, we show… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2005
2005
Acquired resistance to classic caspase-mediated apoptosis is a common problem for the treatment of human cancer. Here, we show… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2002
2002
1'-[4-[1-(4-Fluorophenyl)-1H-indol-3-yl]-1-butyl]spiro[isobenzofuran-1(3H),4'-piperidine] (Lu 28-179) or Siramesine is a sigma… (More)
Is this relevant?
Review
2001
Review
2001
Siramesine is a sigma2 opioid agonist under development by H Lundbeck as a potential treatment for anxiety 11678721. In March… (More)
Is this relevant?